MRRS adds "Global Respiratory Drugs Market to 2022 – Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug – omalizumab – approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.

Table of Contents
3 Key Marketed Products 36
3.1 Overview 36
3.2 Advair - GSK 37
3.3 Spiriva - Boehringer Ingelheim, Pfizer 39
3.4 Symbicort - AstraZeneca/Astellas 41
3.5 Singulair (montelukast) - Merck & Co. 43
3.6 Flixotide/Flovent - GSK 45
3.7 Ventolin - GSK 47
3.8 Kalydeco - Vertex 48
3.9 Pulmozyme - Roche 50
3.10 Esbriet - Roche 51
3.11 TOBI - Novartis 53
3.12 Conclusion 54
4 Pipeline Landscape Assessment 56
4.1 Overview 56
4.2 Pipeline Development Landscape 56
4.3 Molecular Targets in the Pipeline 59
4.4 Clinical Trials 61
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 61
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 65
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 68
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 71
4.4.5 Conclusion 74
5 Multi-scenario Market Forecast to 2022 75
5.1 Overall Market Size 75
5.2 Generic Penetration 76
5.3 Revenue Forecast by Molecular Target 79......

List of Tables and Figures 
Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2016 11
Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age 25
Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age 26
Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults 27
Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016 28
Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016 29
Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016 29
Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016 31
Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016 33
Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016 35
Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2016 Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Spiriva, 2016 Table 13: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2016 42.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-respiratory-drugs-market-to-2022-pipeline-and-market-characterized-by-growing-prominence-of-targeted-therapies-with-asthma-and-cystic-fibrosis-leading-the-way

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/